Introduction:
The biologics contract manufacturing industry in the United States is experiencing significant growth, driven by the increasing demand for biologic drugs globally. According to industry reports, the global biologics market is expected to reach $400 billion by 2026. In the United States, there has been a surge in the number of biologics contract manufacturers offering services to pharmaceutical companies looking to outsource their manufacturing needs.
Top 10 Biologics Contract Manufacturers in United States 2026:
1. Lonza Group AG
– Lonza Group AG is a leading biologics contract manufacturer with a production volume of over 100,000 liters annually. The company has a strong track record of delivering high-quality biologic products to its clients.
2. Catalent, Inc.
– Catalent, Inc. is a top player in the biologics contract manufacturing industry, with a market share of 15% in the United States. The company has extensive experience in manufacturing a wide range of biologic drugs.
3. Patheon
– Patheon is a key player in the biologics contract manufacturing market, with a focus on providing customized solutions to its clients. The company has a strong presence in the United States and a growing export market.
4. Boehringer Ingelheim
– Boehringer Ingelheim is a leading biologics contract manufacturer with state-of-the-art facilities in the United States. The company has a production volume of over 50,000 liters annually and a strong reputation for quality.
5. Samsung BioLogics
– Samsung BioLogics is a major player in the biologics contract manufacturing industry, with a trade value of $1 billion in the United States. The company has a strong focus on innovation and technology.
6. WuXi Biologics
– WuXi Biologics is a top biologics contract manufacturer with a market share of 10% in the United States. The company has a strong track record of delivering cost-effective solutions to its clients.
7. AbbVie Contract Manufacturing
– AbbVie Contract Manufacturing is a key player in the biologics contract manufacturing market, with a production volume of over 70,000 liters annually. The company has a strong focus on quality and compliance.
8. Fujifilm Diosynth Biotechnologies
– Fujifilm Diosynth Biotechnologies is a leading biologics contract manufacturer with a trade value of $800 million in the United States. The company has extensive experience in manufacturing complex biologic drugs.
9. KBI Biopharma
– KBI Biopharma is a major player in the biologics contract manufacturing industry, with a production volume of over 60,000 liters annually. The company has a strong reputation for reliability and customer service.
10. Rentschler Biopharma
– Rentschler Biopharma is a key player in the biologics contract manufacturing market, with a market share of 12% in the United States. The company has a strong focus on sustainability and environmental responsibility.
Insights:
The biologics contract manufacturing industry in the United States is poised for continued growth in the coming years, driven by the increasing demand for biologic drugs. With advancements in technology and an emphasis on quality and compliance, top manufacturers are well-positioned to capitalize on this trend. According to industry forecasts, the global biologics market is expected to grow at a CAGR of 8% from 2021 to 2026, presenting opportunities for biologics contract manufacturers to expand their operations and reach new markets. As the industry continues to evolve, companies that prioritize innovation, efficiency, and customer satisfaction will likely emerge as leaders in the market.
Related Analysis: View Previous Industry Report
